漳州片仔癀药业股份有限公司控股股东九龙江集团完成大规模增持计划
要点概览
- 控股股东九龙江集团完成对片仔癀股份增持计划，累计增持金额达4.999976亿元人民币，接近增持计划上限。
- 本次增持股份数量为3,171,311股，占公司总股本的0.53%。九龙江集团持股比例由50.97%提升至51.50%。
- 增持计划已于2026年4月30日提前完成，原计划实施期限为2026年2月1日至2026年7月31日。
- 北京市君致律师事务所出具的法律意见书确认本次增持合法合规，不触发要约收购义务。
- 本次增持不会导致控股股东及实际控制人变更。
详细内容
漳州片仔癀药业股份有限公司（证券代码：600436，简称“片仔癀”）于2026年5月1日发布公告，披露其控股股东漳州市九龙江集团有限公司（以下简称“九龙江集团”）已于2026年4月30日提前完成本次大规模股份增持计划。此次增持计划最初于2026年1月28日披露，原计划在2026年2月1日至2026年7月31日6个月内，通过上海证券交易所集中竞价交易方式，以自有及专项贷款资金，增持公司股份，增持金额区间为人民币3亿元至5亿元。
根据公告，九龙江集团自2026年2月1日至2026年4月30日，累计通过集中竞价方式增持片仔癀股份3,171,311股，占公司总股本0.53%。累计增持金额高达49,999.76万元，几乎达到增持计划的上限。此次增持完成后，九龙江集团合计持有片仔癀股份310,693,954股，持股比例由增持前的50.97%提升至51.50%。
对股东和投资者的重要影响
- 控股股东大手笔增持，显示对公司前景充满信心。控股股东大额增持往往被市场解读为其对公司发展前景的强烈认可，可能对公司股价形成正面推动作用，增强市场信心。
- 增持比例过半，加强控股地位。九龙江集团持股比例提升至51.50%，进一步稳固了其对公司控制权，有助于公司治理结构的稳定。
- 未触发要约收购。本次增持未触及要约收购线，不会导致控股股东或实际控制人变更，有利于公司经营的持续性和稳定性。
- 法律合规性得到第三方权威律所确认。北京市君致律师事务所出具的法律意见书确认九龙江集团具备增持资格，且本次操作符合法律法规和信息披露义务，保障了投资者知情权。
- 资金来源明确，增持资金为自有及专项贷款。表明控股股东具有较强的资金实力与财务安排能力。
投资者应关注事项
- 控股股东增持行为通常被市场视为“看好公司未来”，有望提升市场信心和股价表现。
- 增持完成后，股权结构进一步集中，有利于后续公司决策的高效推进，但也需关注大股东持股比例过高带来的治理平衡问题。
- 本次增持未带来实际控制权变更，也未触发要约收购等特殊程序，属正常增持行为。
结论
本次控股股东大额增持行为无疑是片仔癀近期具有重要意义的资本运作事件。九龙江集团以接近上限的资金完成增持，增强控股地位，有望对公司股价及市场信心带来积极影响，值得投资者持续关注。
免责声明：本文仅基于公开披露信息整理，不构成任何投资建议。股市有风险，投资需谨慎。
Zhanzhou Pien Tze Huang Pharmaceutical Co., Ltd. Controlling Shareholder Jiulongjiang Group Completes Major Shareholding Increase Plan
Key Highlights
- Controlling shareholder Jiulongjiang Group has completed its planned shareholding increase in Pien Tze Huang, with a total investment of RMB 499.9976 million, nearly reaching the upper limit of the plan.
- The number of shares added is 3,171,311, accounting for 0.53% of the company’s total share capital. Jiulongjiang Group’s shareholding rose from 50.97% to 51.50%.
- The shareholding increase was completed ahead of schedule on April 30, 2026, while the original plan was to run until July 31, 2026.
- Legal opinion provided by Beijing Junzhi Law Firm confirmed the legality and compliance of the increase, which does not trigger a mandatory takeover offer.
- This shareholding increase does not cause any change in controlling shareholder or actual controller.
Details
Zhanzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Stock Code: 600436, “Pien Tze Huang”) announced on May 1, 2026, that its controlling shareholder, Zhanzhou Jiulongjiang Group Co., Ltd. (“Jiulongjiang Group”), has completed its major shareholding increase plan ahead of schedule. The plan was first disclosed on January 28, 2026, and originally scheduled to run from February 1 to July 31, 2026, with a planned investment between RMB 300 million and RMB 500 million via the Shanghai Stock Exchange’s centralized bidding system, using its own and special loan funds.
According to the announcement, Jiulongjiang Group increased its shareholding by 3,171,311 shares (0.53% of total shares) between February 1 and April 30, 2026, investing a total of RMB 499.9976 million—nearly the upper limit. After this increase, Jiulongjiang Group holds 310,693,954 shares, raising its holding from 50.97% to 51.50%.
Significance for Shareholders and Investors
- Large-scale share purchase by controlling shareholder demonstrates strong confidence in the company’s prospects. Such moves are often interpreted by the market as a positive signal and may boost share prices and market confidence.
- Shareholding exceeds 51%, further consolidating control. This enhances governance stability and decision-making efficiency.
- No mandatory takeover triggered. The increase does not cross thresholds requiring a takeover, nor does it change the controlling party, promoting continuity and stability.
- Third-party legal confirmation of compliance. The legal opinion from Beijing Junzhi Law Firm affirms that the increase is legal and all information disclosure obligations were fulfilled.
- Clear funding sources. The use of both self-owned and special loan funds shows the financial strength and planning of the controlling shareholder.
Investor Considerations
- This move is typically interpreted as a “vote of confidence” in the company’s future and may positively impact the share price.
- Increased concentration of shareholding may facilitate efficient decision-making, but investors should also be mindful of governance balance issues with high shareholder concentration.
- No actual controller or major changes in governance result from this move; this is a normal increase in shareholding.
Conclusion
This major increase in shareholding by the controlling shareholder is a significant event for Pien Tze Huang. Jiulongjiang Group’s substantial investment, nearing the maximum planned amount, further strengthens its control and may positively affect the company’s stock price and market sentiment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to risk. Please invest cautiously.
